Flinton Capital Management’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Flinton Capital Management’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,224	Closed	-$51K	–	894
2019 Q1	$51K	Buy	+1,224	New	+$49.8K	﹤0.01%	814

Other funds holding XPH

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

HCIA

Hochman Cole Investment Advisors Deerfield, Illinois $255M AUM 23.27% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Flinton Capital Management's XPH Position: Q2 2019 in Review

Flinton Capital Management sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q2 2019, closing a stake of 1,224 shares — an estimated $51K sold.

Flinton Capital Management first reported a position in XPH in Q1 2019 and held it in 1 quarter. The position peaked at $51K in Q1 2019. 61 funds tracked by Wall St. Rank hold XPH as of Q2 2019.

Flinton Capital Management reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q2 2019 after selling out during the quarter.
Flinton Capital Management sold 1,224 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2019, an estimated $51K.
Flinton Capital Management first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q1 2019 and held it in 1 quarter.
Flinton Capital Management's State Street SPDR S&P Pharmaceuticals ETF position peaked at $51K in Q1 2019.
61 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2019.

Based on Flinton Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.